
Wendell Miley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1646354/publications.pdf Version: 2024-02-01



Wendell Miley

#	Article	IF	CITATIONS
1	Inhibition of cGAS DNA Sensing by a Herpesvirus Virion Protein. Cell Host and Microbe, 2015, 18, 333-344.	11.0	223
2	Viral, immunologic, and clinical features of primary effusion lymphoma. Blood, 2019, 133, 1753-1761.	1.4	87
3	Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: A new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. Journal of Immunological Methods, 2010, 356, 39-46.	1.4	61
4	Heterogeneity and Breadth of Host Antibody Response to KSHV Infection Demonstrated by Systematic Analysis of the KSHV Proteome. PLoS Pathogens, 2014, 10, e1004046.	4.7	57
5	Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. Infectious Agents and Cancer, 2011, 6, 15.	2.6	55
6	Risk Factors for Seropositivity to Kaposi Sarcoma–Associated Herpesvirus Among Children in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 228-233.	2.1	51
7	Association between malaria exposure and Kaposi's sarcomaâ€associated herpes virus seropositivity in Uganda. Tropical Medicine and International Health, 2015, 20, 665-672.	2.3	47
8	Transactivation of human endogenous retrovirus K (HERV-K) by KSHV promotes Kaposi's sarcoma development. Oncogene, 2018, 37, 4534-4545.	5.9	43
9	Trends in <scp>K</scp> aposi's sarcomaâ€associated <scp>H</scp> erpesvirus antibodies prior to the development of <scp>HIV</scp> â€associated <scp>K</scp> aposi's sarcoma: A nested caseâ€control study. International Journal of Cancer, 2015, 136, 2822-2830.	5.1	35
10	Kaposi Sarcoma–Associated Herpesvirus in a Rural Ugandan Cohort, 1992–2008. Journal of Infectious Diseases, 2018, 217, 263-269.	4.0	33
11	Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon. Cancer Epidemiology, 2014, 38, 137-143.	1.9	31
12	Mutual detection of Kaposi's sarcomaâ€associated herpesvirus and Epstein–Barr virus in blood and saliva of Cameroonians with and without Kaposi's sarcoma. International Journal of Cancer, 2019, 145, 2468-2477.	5.1	30
13	HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. American Journal of Transplantation, 2022, 22, 853-864.	4.7	30
14	Distinct genetic architectures and environmental factors associate with host response to the \hat{I}^3 2-herpesvirus infections. Nature Communications, 2020, 11, 3849.	12.8	24
15	ORF33 and ORF38 of Kaposi's Sarcoma-Associated Herpesvirus Interact and Are Required for Optimal Production of Infectious Progeny Viruses. Journal of Virology, 2016, 90, 1741-1756.	3.4	22
16	Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and Their Mothers. Journal of Infectious Diseases, 2018, 218, 892-900.	4.0	21
17	Relationship Between Anemia, Malaria Coinfection, and Kaposi Sarcoma-Associated Herpesvirus Seropositivity in a Population-Based Study in Rural Uganda. Journal of Infectious Diseases, 2018, 218, 1061-1065.	4.0	21
18	Risk Factors for Kaposi's Sarcoma–Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda. Clinical Infectious Diseases, 2020, 71, 1055-1062.	5.8	19

WENDELL MILEY

#	Article	IF	CITATIONS
19	Kaposi's sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands. PLoS Neglected Tropical Diseases, 2019, 13, e0007776.	3.0	17
20	Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda. Nature Communications, 2021, 12, 7323.	12.8	13
21	Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV. PLoS Pathogens, 2018, 14, e1007130.	4.7	10
22	Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization. Journal of Clinical Microbiology, 2019, 57, .	3.9	8
23	Hepatitis C virus seroprevalence in the general female population from 8 countries. Journal of Clinical Virology, 2015, 68, 89-93.	3.1	7
24	Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. Aids, 2021, 35, 53-62.	2.2	6
25	Variation in KSHV prevalence between geographically proximate locations in Uganda. Infectious Agents and Cancer, 2020, 15, 49.	2.6	5
26	Everolimus-Induced Remission of Classic Kaposi's Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency. Journal of Clinical Immunology, 2020, 40, 774-779.	3.8	5